KEPA
BELLOSO URIBE
PROFESORADO ADJUNTO
Instituto Biofisika
Lejona, EspañaPublicaciones en colaboración con investigadoras/es de Instituto Biofisika (12)
2024
-
OptiMo-LDLr: An Integrated In Silico Model with Enhanced Predictive Power for LDL Receptor Variants, Unraveling Hot Spot Pathogenic Residues
Advanced Science, Vol. 11, Núm. 13
2023
-
Contribution of APOE Genetic Variants to Dyslipidemia
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 43, Núm. 6, pp. 1066-1077
2022
-
Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model
Small, Vol. 18, Núm. 13
-
Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 42, Núm. 7, pp. E203-E216
2021
-
MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants
JACC: Basic to Translational Science, Vol. 6, Núm. 11, pp. 815-827
2020
-
Cholesterol efflux efficiency of reconstituted HDL is affected by nanoparticle lipid composition
Biomedicines, Vol. 8, Núm. 10
-
Pathophysiology of type 2 diabetes mellitus
International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-34
-
Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights
International Journal of Molecular Sciences, Vol. 21, Núm. 13, pp. 1-25
2019
-
Membrane permeabilization by pore-forming rtx toxins: What kind of lesions do these toxins form?
Toxins, Vol. 11, Núm. 6
-
The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9
Atherosclerosis, Vol. 289, pp. 162-172